Viridian Therapeutics, Inc. $VRDN Stock Holdings Trimmed by Candriam S.C.A.

Candriam S.C.A. lessened its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 9.3% in the first quarter, HoldingsChannel reports. The fund owned 711,739 shares of the company’s stock after selling 73,359 shares during the period. Candriam S.C.A.’s holdings in Viridian Therapeutics were worth $13,922,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. ANTIPODES PARTNERS Ltd acquired a new position in shares of Viridian Therapeutics during the fourth quarter valued at $36,000. Larson Financial Group LLC bought a new stake in shares of Viridian Therapeutics during the third quarter valued at about $52,000. US Bancorp DE lifted its holdings in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Viridian Therapeutics in the fourth quarter worth about $176,000. Finally, Ensign Peak Advisors Inc bought a new position in Viridian Therapeutics in the 4th quarter valued at about $201,000.

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,176,470 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the completion of the acquisition, the director owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This represents a 30.05% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a research note on Monday, June 29th. Wedbush upped their price target on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings cut shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.79.

Viridian Therapeutics Price Performance

NASDAQ:VRDN opened at $19.74 on Monday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The business’s 50-day moving average price is $17.30 and its 200 day moving average price is $23.30. Viridian Therapeutics, Inc. has a 52-week low of $13.18 and a 52-week high of $34.29. The firm has a market cap of $2.03 billion, a P/E ratio of -5.95 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. During the same period in the prior year, the company earned ($0.87) EPS. Viridian Therapeutics’s revenue was up 95.8% on a year-over-year basis. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.